Navigation Links
Prism Pharmaceuticals' Study of Injectable Clopidogrel Accepted for Presentation at the American College of Cardiology
Date:2/9/2009

- First time IV formulation of clopidogrel, the active ingredient in

PLAVIX(R), is studied in humans -

KING OF PRUSSIA, Pa., Feb. 9 /PRNewswire/ -- Prism Pharmaceuticals announced today that the results of the first-in-man study of PM103, a novel intravenous formulation of clopidogrel bisulfate (the active ingredient in PLAVIX(R)), has been accepted for poster presentation at the 58th Scientific Session of the American College of Cardiology (ACC) on March 29-31, 2009. The poster will be presented at the ACC's Innovation in Intervention: i2 Summit 2009 in partnership with Cardiovascular Research Foundation.

    Presentation Number: 2515-749

    Abstract Title:     Assessment of the pharmacokinetic and pharmacodynamic
                        effects of intravenous clopidogrel in humans

    Time:               Monday, Mar 30, 2009, 9:30 AM -10:30 AM

    Topic:              Pharmacotherapy - Interventional Aspects

    Authors:            Daniel Cushing, Raymond Lipicky, Peter Kowey,
                        Christopher Cannon, Michael Adams, Warren Cooper,
                        Gerold Mosher, Prism Pharmaceuticals

"We are very pleased to present the first data in humans of an IV formulation of clopidogrel at this most prestigious cardiology scientific session," said Dr. Warren D. Cooper, President and CEO of Prism. "PM103 is Prism's second acute care cardiovascular product that is being developed through our accelerated model, which focuses on bringing novel and improved formulations of existing compounds to the market."

About PM103

PM103 is a proprietary, novel intravenous formulation of clopidogrel bisulfate. Clopidogrel is the active ingredient in PLAVIX(R) (clopidogrel bisulfate), an orally available antiplatelet drug marketed by Bristol-Myers Squibb and sanofi-aventis. PM103 is being developed in collaboration with CyD
'/>"/>

SOURCE Prism Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Prism Pharmaceuticals Appoints Maurits Geerlings Vice President of Business Development
2. New Empire BlueCross BlueShield Prism Plans Offer Better Choice and Affordability for New York Small Group Market
3. Prism glasses expand the view for patients with hemianopia
4. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
5. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... The National Resident Matching Program has published ... of the relationship between unique applicant characteristics and success ... edition is based on the 2014 Main Residency Match ... school senior students and all other applicants. , ... new edition of Charting Outcomes in the Match,” said ...
(Date:9/17/2014)... 18, 2014 ADVOCATE, the premier ... announces today that they have been awarded the ... in Fort Wayne, Indiana. , ADVOCATE ... encompassing their proprietary suite of billing process software ... improves radiology billing and data quality consistency by ...
(Date:9/17/2014)... 2014 According to an August ... titled “Adverse Events Associated with Use of Enhancement ... unapproved use of Expression, a hyaluronic acid product, ... reactions including discoloration, lumps, bruising, nodules, and swelling. ... for cosmetic use include Restylane , Juvéderm, ...
(Date:9/17/2014)... 17, 2014 As kinship care continues ... who cannot live with their parents, emphasis on kinship ... to enhance services and supports for kinship caregivers and ... National Kinship Care Conference is being held this week ... best practice, policy, program and service development for kinship ...
(Date:9/17/2014)... 17, 2014 Sunday night saw ... and ushered in a new national spokesperson for ... America Organization’s official national platform, Children’s Miracle ... newest National Goodwill Ambassador. , Kazantsev’s year in ... Network Hospitals across the U.S., visiting with patients ...
Breaking Medicine News(10 mins):Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
... July 9, 2009 The President of the ... statement today on President Obama,s nomination of Francis Collins, M.D., ... Health (NIH):,"At no other time in recent memory has there ... in the power of science to deliver solutions to the ...
... Bioheart, Inc. (OTC Bulletin Board: BHRT) (the "Company") ... July 7, 2009, Bioheart, Inc. (the "Company") has received proceeds ... common stock and warrants under its current offering under Regulation ... Common Stock to be issued in connection with the Offering ...
... Parsippany took top honors in the state,s first-ever 100-day ... on June 2nd. With participating residents losing an average of ... pounds, Parsippany was presented with a plaque and Morris County ... , Residents throughout northern and central New Jersey also participated ...
... , ... and Directory Helps Attendees and Exhibitors,Connect at AAMSE Conference and Beyond. , ... Arlington, VA (PRWEB) July 9, 2009 -- MarketArt ... enhanced attendee experience at the American Association of Medical Society Executives (AAMSE) 2009 ...
... Institute of Technology (Caltech) and the Scripps Research Institute have ... chemicals that have the potential to take the place of ... James R. Heath, the Elizabeth W. Gilloon Professor and ... M. Keck Professor of Chemistry at the Scripps Research Institute ...
... United States Senate Committee on Small Business ... Member Olympia J. Snowe, R-Maine, today convened a ... relate to small businesses. Participants at the roundtable, ... the Perspective of Small Businesses," included U.S. Sen. ...
Cached Medicine News:Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 2Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 3Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 2Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 3Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 2Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 3Health News:Caltech chemists say antibody surrogates are just a 'click' away 2Health News:Caltech chemists say antibody surrogates are just a 'click' away 3Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3
(Date:9/17/2014)... According to a new market research report ... Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, Diagnosis, ... Global Forecast to 2020", published by MarketsandMarkets, the total ... $56.50 Billion by 2020, growing at a CAGR of ... market data Tables and 71 Figures spread through 312 ...
(Date:9/17/2014)... , Sept. 17, 2014 An analysis ... regarding patients taking Sovaldi® (sofosbuvir), a new and expensive ... shows that over the last several months (May through ... downward trend in Sovaldi utilization. This suggests another surge ... new therapeutic regimens of similar efficacy and shorter duration ...
(Date:9/17/2014)... MORRISTOWN, N.J. , Sept. 17, 2014 /PRNewswire/ ... LLP (MDM&C), today announced that it will serve ... the Benefits and Avoiding the Risks of Healthcare ... 2014 that will examine delivery systems, reimbursement, compliance ... Affordable Care Act. Logo -  ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... Members and Staff Will Focus on Advances in ... Research and Treatment of Lung Cancer in Women, SEATTLE, ... with the Society for Women,s Health,Research, the Lung Cancer Alliance ... Female Matters to Research," on,Capitol Hill to discuss advances in ...
... results outline dabigatran etexilate as potential thromboprophylaxis ... hip replacement surgery, RIDGEFIELD, Conn., Sept. 13 ... issue of The Lancet will publish results,from the ... therapy for patients undergoing total hip replacement surgery(1).,The ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 2Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill 3The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 2The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor 3
... The Venus-i Laser System is a ... laser system with applications in dermatology, cosmetic ... ophthalmology. An ideal laser for skin resurfacing, ... most powerful, Erbium:YAG lasers on the market. ...
... Laser System is a new, portable, light ... applications in dermatology, cosmetic and plastic surgery, ... laser for skin resurfacing, it is the ... lasers on the market. It provides an ...
... biolitecs Ceralas D 980 nm diode ... clean, bloodless field for most surgical procedures. ... D cuts optically without collateral tissue ... laser coagulates blood instantly and seals small ...
... The APTIMA COMBO 2 Assay is ... that uses target capture for in vitro ... CT and GC. The assay uses a ... capture (TC), Transcription-Mediated Amplification (TMA) and Dual ...
Medicine Products: